Design Therapeutics, Inc. (DSGN)

US — Healthcare Sector
Peers: GLUE  HOWL  IKNA  STOK  ACHL  NLTX  MGTA  GRPH  ALXO  AADI  ADCT  ALVR  GRCL  THRX  ERAS  CGEM  IMCR  CCCC 

Automate Your Wheel Strategy on DSGN

With Tiblio's Option Bot, you can configure your own wheel strategy including DSGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol DSGN
  • Rev/Share 0.0
  • Book/Share 4.0156
  • PB 0.9289
  • Debt/Equity 0.0094
  • CurrentRatio 28.3686
  • ROIC -0.2973

 

  • MktCap 211747251.0
  • FreeCF/Share -0.8399
  • PFCF -4.4418
  • PE -3.7672
  • Debt/Assets 0.009
  • DivYield 0
  • ROE -0.2285

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 4
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
DSGN
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral

Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025 Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025

Read More
image for news Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

About Design Therapeutics, Inc. (DSGN)

  • IPO Date 2021-03-29
  • Website https://www.designtx.com
  • Industry Biotechnology
  • CEO Mr. Pratik Shah Ph.D.
  • Employees 56
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.